目的：评价扶正化瘀方对不同病理阶段四氯化碳（CCl4）大鼠肝纤维化及活化星状细胞的影响。方法：用CCl4复合法制备大鼠肝纤维化模型，干预组分别于造模之日、2周末、4周末起以扶正化瘀方稀释液灌胃，在第2、4、6周末分批处死大鼠，观察各组大鼠肝组织病理学，采用计算机图像分析测定大鼠肝组织纤维化面积比例；测定α-平滑肌肌动蛋白（α-SMA）的积分光密度（IOD）值。组间数据比较用完全随机设计的单因素方差分析。结果：随着造模时间的延长，与正常组比较，2、4、6周末模型组、各干预组肝组织纤维化面积比例明显升高，α-SMA表达亦均有升高（P＜0．05）；与模型组比较，各干预组大鼠肝组织纤维化面积比例均减少，大鼠肝组织α-SMA的表达均有下调，且均为药物干预一组下降显著（P＜0．05）。结论：扶正化瘀方在不同病理阶段均减少了α-SMA的表达，具有抗肝纤维化的作用，且越早进行干预治疗效果越好。%Objective To evaluate the influence of Fuzheng Huayu decoction on different pathological stages fibrotic liver tissue and activated hepatic stellate cells (HSCs). Methods Use a carbon tetrachloride (CCl4)-induced liver cirrhosis rat model system. The drug intervention was administered via oral-gastric irrigation in building, the end of week 2 and 4. Rats were batch sacrificed at the end of week 2 , 4, and 6. Liver fibrosis was evaluated by histology, and expression of a-smooth muscle actin (α-SMA) was determined by immunohistochemistry. Between-group comparisons were made by completely random design and ANOVA with Bonferroni correction. Results At the end of weeks 2, 4 and 6, the model group and drug intervention groups had significantly higher area ratio of liver fibrosis and higher expression of α-SMA than the normal group, but the three drug intervention groups had significantly less area ratio of liver fibrosis and less expression of α-SMA than the model group and the drug intervention 1 group showed the most robust decrease (P<0.05). Conclusion The Fuzheng Huayu decoction leads to down-regulated α-SMA expression and reduced degree of liver fibrosis on different pathological stages of fibrotic liver tissue, and the earlier drug intervention, the better the results.
展开▼
